Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
0.3921
+0.0251 (6.84%)
At close: Sep 12, 2025, 4:00 PM EDT
0.3928
+0.0007 (0.18%)
Pre-market: Sep 15, 2025, 8:19 AM EDT
Femasys Revenue
Femasys had revenue of $409.27K in the quarter ending June 30, 2025, with 84.78% growth. This brings the company's revenue in the last twelve months to $1.89M, up 98.61% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$1.89M
Revenue Growth
+98.61%
P/S Ratio
5.15
Revenue / Employee
$26,578
Employees
71
Market Cap
16.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
FEMY News
- 3 days ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 6 days ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 20 days ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewsWire
- 5 weeks ago - Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewsWire
- 2 months ago - Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic - GlobeNewsWire
- 2 months ago - Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control - GlobeNewsWire
- 3 months ago - Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth - GlobeNewsWire